Advances in lopinavir formulations: strategies to overcome solubility, bioavailability, and stability challenges
DOI:
https://doi.org/10.56782/pps.280Keywords:
Antiretroviral therapy, Drug delivery systems, Bioavailability, HIV treatment, PharmacokineticsAbstract
Lopinavir, a key protease inhibitor in antiretroviral therapy, faces significant challenges related to its poor solubility, low bioavailability, and low stability, which limit its therapeutic efficacy. This review explores a range of advanced formulation strategies developed to overcome these limitations, enhancing lopinavir’s delivery and effectiveness. Nanoparticle-based systems such as solid lipid nanoparticles, nanostructured lipid carriers, and lipid-polymer hybrid systems demonstrate notable improvements in bioavailability, drug release, and lymphatic targeting. Additionally, solid dosage formulations like amorphous solid dispersions and proliposomes have been shown to significantly enhance solubility and stability, improving lopinavir’s pharmacokinetic profile. By reviewing the preparation techniques, in vivo results, and comparative advantages of these innovative delivery systems, this article provides insight into their potential to optimize lopinavir-based therapies. Furthermore, the review discusses the role of these strategies in addressing adherence issues, ultimately improving patient outcomes. Continued research into the novel approaches is essential for advancing lopinavir delivery and enhancing its clinical efficacy in the treatment of HIV.
Downloads
References
1. Aronson, J.K. Lopinavir. In Meyler's Side Effects of Drugs (Sixteenth Edition), Elsevier, 2016; pp. 669-675. DOI: https://doi.org/10.1016/B978-0-444-53717-1.00993-8
2. Eckhardt, B.J.; Gulick, R.M. Drugs for HIV Infection. In Opal, Infectious Diseases, 4th ed.; Jonathan, C., William, G.; Eds.; Elsevier, 2017: pp.1293-1308. DOI: https://doi.org/10.1016/B978-0-7020-6285-8.00152-0
3. Muralidharan, N.; Sakthivel, R.; Velmurugan, D.; Gromiha, M. M. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19. J. Biomol. Struct. Dyn. 2021, 39(7), 2673-2678. DOI: https://doi.org/10.1080/07391102.2020.1752802
4. Eche, S.; Kumar, A.; Sonela, N.; Gordon, M.L. Acquired HIV-1 protease conformational flexibility associated with lopinavir failure may shape the outcome of darunavir therapy after antiretroviral therapy switch. Biomolecules 2021, 11(4), Art. No: 489. DOI: 10.3390/biom11040489 DOI: https://doi.org/10.3390/biom11040489
5. Mahdi, M.; Mótyán, J.A.; Szojka, Z.I.; Golda, M.; Miczi, M.; Tőzsér, J. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′ s main protease. Virol. J. 2020, 17(190), 1-8. DOI: 10.1186/s12985-020-01457-0 DOI: https://doi.org/10.1186/s12985-020-01457-0
6. Ghosh, A.K.; Osswald, H.L.; Prato, G. Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS. J. Med. Chem. 2016, 59(11), 5172-5208. DOI: 10.1021/acs.jmedchem.5b01697 DOI: https://doi.org/10.1021/acs.jmedchem.5b01697
7. Von der Helm, K. Retroviral proteases: Structure, function and inhibition-from a non-anticipated viral enzyme to the target of a most promising HIV therapy. Biol. Chem. 1996, 377(12), 765-774. DOI: 10.1515/bchm3.1996.377.12.765 DOI: https://doi.org/10.1515/bchm3.1996.377.12.765
8. Ho, W.S.; Zhang, R.; Tan, Y.L.; Chai, C.L. COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt? Pharmacol. Res. 2022, 179, Art. No: 106201. DOI: 10.1016/j.phrs.2022.106201 DOI: https://doi.org/10.1016/j.phrs.2022.106201
9. Marin, R.C.; Behl, T.; Negrut, N.; Bungau, S. Management of antiretroviral therapy with boosted protease inhibitors—darunavir/ritonavir or darunavir/cobicistat. Biomedicines 2021, 9(3), Art. No: 313. DOI: 10.3390/biomedicines9030313 DOI: https://doi.org/10.3390/biomedicines9030313
10. ter Heine, R.; Van Waterschoot, R.A.; Keizer, R.J.; Beijnen, J.H.; Schinkel, A.H.; Huitema, A.D. An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. J. Pharm. Sci. 2011, 100(6), 2508-2515. DOI: 10.1002/jps.22457 DOI: https://doi.org/10.1002/jps.22457
11. Kandel, S.E.; Lampe, J.N. Inhibition of CYP3A7 DHEA-S oxidation by lopinavir and ritonavir: an alternative mechanism for adrenal impairment in HIV antiretroviral-treated neonates. Chem. Res. Toxicol. 2021, 34(4), 1150-1160. DOI: 10.1021/acs.chemrestox.1c00028 DOI: https://doi.org/10.1021/acs.chemrestox.1c00028
12. Hul, M.W.; Montaner, J.S. Ritonavir-boosted protease inhibitors in HIV therapy. Ann. Med. 2011, 43(5), 375-388. DOI: 10.3109/07853890.2011.572905 DOI: https://doi.org/10.3109/07853890.2011.572905
13. Juan, C.; Jiang, X.; Qiang, Z. Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients. Chin. Med. J. 2014, 127(14), 2632-2636. DOI: 10.3760/cma.j.issn.0366-6999.20140538
14. Lepage, M.A.; Rozza, N.; Kremer, R.; Grunbaum, A. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: A retrospective series. Clin. Toxicol. 2021, 59(7), 644-647. DOI: 10.1080/15563650.2020.1842882 DOI: https://doi.org/10.1080/15563650.2020.1842882
15. Badowski, M.E.; Burton, B.; Shaeer, K.M.; Dicristofano, J. Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions, and other considerations for clinical use. Drugs. Context. 2019, 8, 1-31. DOI: 10.7573/dic.212550 DOI: https://doi.org/10.7573/dic.212550
16. Giacomelli, A.; Pezzati, L.; Rusconi, S. The crosstalk between antiretrovirals pharmacology and HIV drug resistance. Expert. Rev. Clin. Pharmacol. 2020, 13(7), 739-760. DOI: 10.1080/17512433.2020.1782737 DOI: https://doi.org/10.1080/17512433.2020.1782737
17. Nastri, B.M.; Pagliano, P.; Zannella, C.; Folliero, V.; Masullo, A.; Rinaldi, L.; Galdiero, M.; Franci, G. HIV and drug-resistant subtypes. Microorganisms 2023, 11(1), Art. No: 221. DOI: 10.3390/microorganisms11010221 DOI: https://doi.org/10.3390/microorganisms11010221
18. Wensing, A.M.; van Maarseveen, N.M.; Nijhuis, M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. Antiviral. Res. 2010, 85(1), 59-74. DOI: 10.1016/j.antiviral.2009.10.003 DOI: https://doi.org/10.1016/j.antiviral.2009.10.003
19. Su, B.; Wang, Y.; Zhou, R.; Jiang, T.; Zhang, H.; Li, Z.; Liu, A.; Shao, Y.; Hua, W.; Zhang, T.; Wu, H. Efficacy and tolerability of lopinavir/ritonavir-and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing, China. Front. Pharmacol. 2019, 10, Art. No: 1472. DOI: 10.3389/fphar.2019.01472 DOI: https://doi.org/10.3389/fphar.2019.01472
20. Gandhi, R.T.; Bedimo, R.; Hoy, J.F.; Landovitz, R.J.; Smith, D.M.; Eaton, E.F.; Lehmann, C.; Springer, S.A.; Sax, P.E.; Thompson, M.A.; Benson, C.A.; Buchbinder, S.P.; Del Rio, C.; Eron Jr, J.J.; Günthard, H.F.; Molina, J.M.; Jacobsen, D.M.; Saag, M.S. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society–USA panel. JAMA 2023, 329(1), 63-84. DOI: 10.1001/jama.2022.22246 DOI: https://doi.org/10.1001/jama.2022.22246
21. Pasley, M.V.; Martinez, M.; Hermes, A.; d'Amico, R.; Nilius, A. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review. AIDS. Rev. 2013, 15(1), 38-48. DOI: 10.1080/15284336.2018.1459343 DOI: https://doi.org/10.1080/15284336.2018.1459343
22. Eggleton, J.S.; Nagalli, S. Highly Active Antiretroviral Therapy (HAART). In: StatPearls [Internet], Eds.; StatPearls: Treasure Island (FL), 2024. Available online: https://www.ncbi.nlm.nih.gov/books/NBK554533/ (accessed 23 September 2024)
23. Hamers, R.L.; de Wit, T.F.; Holmes, C.B. HIV drug resistance in low-income and middle-income countries. Lancet HIV 2018, 5(10), e588-e596. DOI: 10.1016/S2352-3018(18)30173-5 DOI: https://doi.org/10.1016/S2352-3018(18)30173-5
24. Zi, P.; Zhang, C.; Ju, C.; Su, Z.; Bao, Y.; Gao, J.; Sun, J.; Lu, J.; Zhang, C. Solubility and bioavailability enhancement study of lopinavir solid dispersion matrixed with a polymeric surfactant-Soluplus. Eur. J. Pharm. Sci. 2019, 134, 233-245. DOI: 10.1016/j.ejps.2019.04.022 DOI: https://doi.org/10.1016/j.ejps.2019.04.022
25. Khan, A.A.; Mudassir, J.; Akhtar, S.; Murugaiyah, V.; Darwis, Y. Freeze-dried lopinavir-loaded nanostructured lipid carriers for enhanced cellular uptake and bioavailability: statistical optimization, in vitro and in vivo evaluations. Pharmaceutics 2019, 11(2), Art. No: 97. DOI: 10.3390/pharmaceutics11020097 DOI: https://doi.org/10.3390/pharmaceutics11020097
26. Angshuman, B.; Bhattacharjee, S.K.; Mahanta, R.; Biswanth, M.; Bandyopadhaya, S.K. Alginate based nanoparticulate drug delivery for anti-HIV drug lopinavir. J. Global. Pharm. Tech. 2010, 2(3), 126-132. DOI: https://doi.org/10.18579/jpcrkc/2009/8/2/79776
27. Jain, S.; Sharma, J.M.; Jain, A.K.; Mahajan, R.R. Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir. Nanomedicine 2013, 8(10), 1639-1655. DOI: 10.2217/nnm.12.181 DOI: https://doi.org/10.2217/nnm.12.181
28. Ravi, P.R.; Vats, R.; Balija, J.; Adapa, S.P.; Aditya, N. Modified pullulan nanoparticles for oral delivery of lopinavir: Formulation and pharmacokinetic evaluation. Carbohydr. Polym. 2014, 110, 320-328. DOI: 10.1016/j.carbpol.2014.03.099 DOI: https://doi.org/10.1016/j.carbpol.2014.03.099
29. Ravi, P.R.; Vats, R.; Dalal, V.; Gadekar, N.; Adoitya, N. Design, optimization and evaluation of poly-ɛ-caprolactone (PCL) based polymeric nanoparticles for oral delivery of lopinavir. Drug. Dev. Ind. Pharm. 2015, 41(1), 131-140. DOI: 10.3109/03639045.2013.850710 DOI: https://doi.org/10.3109/03639045.2013.850710
30. Joshi, G.; Kumar, A.; Sawant, K. Bioavailability enhancement, Caco-2 cells uptake and intestinal transport of orally administered lopinavir-loaded PLGA nanoparticles. Drug. Deliv. 2016, 23(9), 3492-3504. DOI: 10.1080/10717544.2016.1199605. DOI: https://doi.org/10.1080/10717544.2016.1199605
31. Abou-El-Naga, I.F.; El Kerdany, E.D.; Mady, R.F.; Shalaby, T.I.; Zaytoun, E.M. The effect of lopinavir/ritonavir and lopinavir/ritonavir loaded PLGA nanoparticles on experimental toxoplasmosis. Parasitol. Int. 2017, 66(6), 735-747. DOI: 10.1016/j.parint.2017.08.007 DOI: https://doi.org/10.1016/j.parint.2017.08.007
32. Liptrott, N.J.; Giardiello, M.; McDonald, T.O.; Rannard, S.P.; Owen, A. Lack of interaction of lopinavir solid drug nanoparticles with cells of the immune system. Nanomedicine 2017, 12(17), 2043-2054. DOI: 10.2217/nnm-2017-0095 DOI: https://doi.org/10.2217/nnm-2017-0095
33. Nassar, T.; Rohald, A.; Naraykin, N.; Barasch, D.; Amsalem, O.; Prabhu, P.; Kotler, M.; Benita, S. Nanocapsules embedded in microparticles for enhanced oral bioavailability and efficacy of Lopinavir as an anti-AIDS drug. J. Drug. Target. 2019, 27(5-6), 590-600. DOI: 10.1080/1061186X.2018.1552275 DOI: https://doi.org/10.1080/1061186X.2018.1552275
34. Katata-Seru, L.; Ojo, B.M.; Okubanjo, O.; Soremekun, R.; Aremu, O.S. Nanoformulated Eudragit lopinavir and preliminary release of its loaded suppositories. Heliyon 2020, 6(5), Art. No: e03890. DOI: 10.1016/j.heliyon.2020.e03890 DOI: https://doi.org/10.1016/j.heliyon.2020.e03890
35. Patel, G.; Shelat, P.; Lalwani, A. Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment. Drug. Deliv. 2016, 23(8), 3027-3042. DOI: 10.3109/10717544.2016.1141260 DOI: https://doi.org/10.3109/10717544.2016.1141260
36. Khan, A.A.; Akhtar, S.; Yadav, Y.; Atiya, A.; Alelwani, W.; Bannunah, A.M.; Mahmood, S. Lopinavir-Loaded Self-Nanoemulsifying Drug Delivery System for Enhanced Solubility: Development, Characterisation and Caco-2 Cell Uptake. Curr. Drug. Deliv. 2023, 20(10), 1474-1486. DOI: 10.2174/1567201819666220817111054 DOI: https://doi.org/10.2174/1567201819666220817111054
37. Garg, B.; Katare, O.P.; Beg, S.; Lohan, S.; Singh, B. Systematic development of solid self-nanoemulsifying oily formulations (S-SNEOFs) for enhancing the oral bioavailability and intestinal lymphatic uptake of Lopinavir. Colloids. Surf. B: Biointerfaces 2016, 141, 611-622. DOI: 10.1016/j.colsurfb.2016.02.012 DOI: https://doi.org/10.1016/j.colsurfb.2016.02.012
38. Maniyar, M.G.; Kokare, C.R. Formulation and evaluation of spray dried liposomes of lopinavir for topical application. J. Pharm. Investig. 2019, 49, 259-270. DOI: 10.1007/s40005-018-0403-7 DOI: https://doi.org/10.1007/s40005-018-0403-7
39. Patel, K.K.; Kumar, P.; Thakkar, H.P. Formulation of niosomal gel for enhanced transdermal lopinavir delivery and its comparative evaluation with ethosomal gel. AAPS. Pharm. Sci. Tech. 2012, 13, 1502-1510. DOI: 10.1208/s12249-012-9871-7 DOI: https://doi.org/10.1208/s12249-012-9871-7
40. Fayed, N.D.; Essa, E.A.; El Maghraby, G.M. Menthol augmented niosomes for enhanced intestinal absorption of lopinavir. Pharm. Dev. Technol. 2022, 27(9), 956-964. DOI: 10.1080/10837450.2022.2136195 DOI: https://doi.org/10.1080/10837450.2022.2136195
41. Alex, M.A.; Chacko, A.J.; Jose, S.; Souto, E.B. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur. J. Pharm. Sci. 2011, 42(1-2), 11-18. DOI:10.1016/j.ejps.2010.10.002 DOI: https://doi.org/10.1016/j.ejps.2010.10.002
42. Alex, A.; Paul, W.; Chacko, A.J.; Sharma, C.P. Enhanced delivery of lopinavir to the CNS using Compritol®-based solid lipid nanoparticles. Ther. Deliv. 2011, 2(1), 25-35. Doi: 10.4155/tde.10.96 DOI: https://doi.org/10.4155/tde.10.96
43. Negi, J.S.; Chattopadhyay, P.; Sharma, A.K.; Ram, V. Development of solid lipid nanoparticles (SLNs) of lopinavir using hot self nano-emulsification (SNE) technique. Eur. J. Pharm. Sci. 2013, 48(1-2), 231-239. DOI: 10.1016/j.ejps.2012.10.022 DOI: https://doi.org/10.1016/j.ejps.2012.10.022
44. Ravi, P.R.; Vats, R.; Dalal, V.; Murthy, A.N. A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation. J. Pharm. Pharmacol. 2014, 66(7), 912-926. DOI: 10.1111/jphp.12217 DOI: https://doi.org/10.1111/jphp.12217
45. Ravi, P.R.; Vats, R. Comparative pharmacokinetic evaluation of lopinavir and lopinavir-loaded solid lipid nanoparticles in hepatic impaired rat model. J. Pharm. Pharmacol. 2017, 69(7), 823-833. DOI: 10.1111/jphp.12716 DOI: https://doi.org/10.1111/jphp.12716
46. Ansari, H.; Singh, P. Formulation and in-vivo evaluation of novel topical gel of lopinavir for targeting HIV. Curr. HIV. Res. 2018, 16(4), 270-279. DOI: 10.2174/1570162X16666180924101650 DOI: https://doi.org/10.2174/1570162X16666180924101650
47. Garg, B.; Beg, S.; Kumar, R.; Katare, O.P.; Singh, B. Nanostructured lipidic carriers of lopinavir for effective management of HIV-associated neurocognitive disorder. J. Drug. Deliv. Sci. Tech. 2019, 53, Art. No: 101220. DOI: 10.1016/j.jddst.2019.101220 DOI: https://doi.org/10.1016/j.jddst.2019.101220
48. Moura, R.B.; Andrade, L.M.; Alonso, L.; Alonso, A.; Marreto, R.N.; Taveira, S.F. Combination of lipid nanoparticles and iontophoresis for enhanced lopinavir skin permeation: Impact of electric current on lipid dynamics. Eur. J. Pharm. Sci. 2022, 168, Art. No: 106048. DOI: 10.1016/j.ejps.2021.106048 DOI: https://doi.org/10.1016/j.ejps.2021.106048
49. Maniyar, M.; Chandak, A.; Kokare, C. Lopinavir loaded spray dried liposomes with penetration enhancers for cytotoxic activity. Infect. Disord. Drug. Targets 2020, 20(5), 724-736. DOI: 10.2174/1871526519666191008112207 DOI: https://doi.org/10.2174/1871526519666191008112207
50. Hamed, R.; Mohamed, E.M.; Sediri, K.; Khan, M.A.; Rahman, Z. Development of stable amorphous solid dispersion and quantification of crystalline fraction of lopinavir by spectroscopic-chemometric methods. Int. J. Pharm. 2021, 602, Art. No: 120657. DOI: 10.1016/j.ijpharm.2021.120657 DOI: https://doi.org/10.1016/j.ijpharm.2021.120657
51. Li, N.; Taylor, L.S. Microstructure formation for improved dissolution performance of lopinavir amorphous solid dispersions. Mol. Pharm. 2019, 16(4), 1751-1765. DOI: 10.1021/acs.molpharmaceut.9b00117 DOI: https://doi.org/10.1021/acs.molpharmaceut.9b00117
52. Kasbaum, F.E.; de Carvalho, D.M.; de Jesus Rodrigues, L.; Cardoso, G.; Pinho, L.A.; Martins, F.T.; Cunha-Filho, M.; Taveira, S.F.; Marreto, R.N. Development of lipid polymer hybrid drug delivery systems prepared by hot-melt extrusion. AAPS. Pharm. Sci. Tech. 2023, 24(6), Art. No: 156. DOI: 10.1208/s12249-023-02610-y DOI: https://doi.org/10.1208/s12249-023-02610-y
53. Kayalar, C.; Helal, N.; Mohamed, E.M.; Dharani, S.; Khuroo, T.; Kuttolamadom, M.A.; Rahman, Z.; Khan, M.A. In Vitro and In Vivo testing of 3D-Printed Amorphous Lopinavir Printlets by Selective Laser Sinitering: Improved Bioavailability of a Poorly Soluble Drug. AAPS. Pharm. Sci. Tech. 2024, 25(1), Art. No: 20. DOI: 10.1208/s12249-023-02729-y DOI: https://doi.org/10.1208/s12249-023-02729-y
54. Fayed, N.D.; Arafa, M.F.; Essa, E.A.; El Maghraby, G.M. Lopinavir-menthol co-crystals for enhanced dissolution rate and intestinal absorption. J. Drug. Deliv. Sci. Technol. 2022, 74, Art. No: 103587. DOI: 10.1016/j.jddst.2022.103587 DOI: https://doi.org/10.1016/j.jddst.2022.103587
55. Yun, T.S.; Jung, M.; Bang, K.H.; Lee, H.K.; Jin, M.; Yoo, H.; Won, J.H.; Song, B.; Hwang, Y.R.; Baek, J.S.; Cho, C.W. An economically advantageous amorphous solid dispersion of the fixed combination of lopinavir and ritonavir. J. Pharm. Investig. 2023, 53(4), 549-561. DOI: 10.1007/s40005-023-00623-0 DOI: https://doi.org/10.1007/s40005-023-00623-0
56. Pham, K.; Li, D.; Guo, S.; Penzak, S.; Dong, X. Development and in vivo evaluation of child-friendly lopinavir/ritonavir pediatric granules utilizing novel in situ self-assembly nanoparticles. J. Control. Release. 2016, 226, 88-97. DOI: 10.1016/j.jconrel.2016.02.001 DOI: https://doi.org/10.1016/j.jconrel.2016.02.001
57. Else, L.J.; Douglas, M.; Dickinson, L.; Back, D.J.; Khoo, S.H.; Taylor, G.P. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob. Agents Chemother. 2012, 56(2), 816-824. DOI: 10.1128/AAC.05186-11 DOI: https://doi.org/10.1128/AAC.05186-11
58. Qin, C.; Chu, Y.; Feng, W.; Fromont, C.; He, S.; Ali, J.; Lee, J.B.; Zgair, A.; Berton, M.; Bettonte, S.; Liu, R. Targeted delivery of lopinavir to HIV reservoirs in the mesenteric lymphatic system by lipophilic ester prodrug approach. J. Control. Release 2021, 329, 1077-1089. DOI: 10.1016/j.jconrel.2020.10.036 DOI: https://doi.org/10.1016/j.jconrel.2020.10.036
59. Patel, G.M.; Shelat, P.K.; Lalwani, A.N. QbD based development of proliposome of lopinavir for improved oral bioavailability. Eur. J. Pharm. Sci. 2017, 108, 50-61. DOI: 10.1016/j.ejps.2016.08.057 DOI: https://doi.org/10.1016/j.ejps.2016.08.057
60. Madgulkar, A.R.; Bhalekar, M.R.; Kadam, A.A. Improvement of oral bioavailability of lopinavir without co-administration of ritonavir using microspheres of thiolated xyloglucan. AAPS. Pharm. Sci. Tech. 2018, 19(1), 293-302. DOI: 10.1208/s12249-017-0834-x DOI: https://doi.org/10.1208/s12249-017-0834-x
61. Patel, D.; Kumar, P.; Thakkar, H.P. Lopinavir metered-dose transdermal spray through microporated skin: Permeation enhancement to achieve therapeutic needs. J. Drug. Deliv. Sci. Tech. 2015, 29, 173-180. DOI: 10.1016/j.jddst.2015.07.004 DOI: https://doi.org/10.1016/j.jddst.2015.07.004
62. Adeoye, O.; Conceição, J.; Serra, P.A.; da Silva, A.B.; Duarte, N.; Guedes, R.C.; Corvo, M.C.; Aguiar-Ricardo, A.; Jicsinszky, L.; Casimiro, T.; Cabral-Marques, H. Cyclodextrin solubilization and complexation of antiretroviral drug lopinavir: In silico prediction; Effects of derivatization, molar ratio and preparation method. Carbohydr. Polym. 2020, 227, Art. No: 115287. DOI: 10.1016/j.carbpol.2019.115287 DOI: https://doi.org/10.1016/j.carbpol.2019.115287
63. Adeoye, O.; Bártolo, I.; Conceição, J.; da Silva, A.B.; Duarte, N.; Francisco, A.P.; Taveira, N.; Cabral-Marques, H. Pyromellitic dianhydride crosslinked soluble cyclodextrin polymers: Synthesis, lopinavir release from sub-micron sized particles and anti-HIV-1 activity. Int. J. Pharm. 2020, 583, Art. No: 119356. DOI: 10.1016/j.ijpharm.2020.119356 DOI: https://doi.org/10.1016/j.ijpharm.2020.119356
64. Mahajan, H.S.; Patil, P.H. Central composite design-based optimization of lopinavir vitamin E-TPGS micelle: In vitro characterization and in vivo pharmacokinetic study. Colloids. Surf. B. Biointerfaces 2020, 194, Art. No: 111149. DOI: 10.1016/j.colsurfb.2020.111149 DOI: https://doi.org/10.1016/j.colsurfb.2020.111149
65. Chaudhari, S.P.; Handge, N.M. Formulation, development and evaluation of lopinavir loaded polymeric micelles. J. Sci. Tech. 2020, 5(4), 173-187. DOI: 10.46243/jst.2020.v5.i4.pp173-187 DOI: https://doi.org/10.46243/jst.2020.v5.i4.pp173-187
66. Aremu, O.S.; Katata-Seru, L.; Mkhize, Z.; Botha, T.L.; Wepener, V. Polyethylene glycol (5,000) succinate conjugate of lopinavir and its associated toxicity using Danio rerio as a model organism. Sci. Rep. 2020, 10(1), Art. No: 11789. DOI: 10.1038/s41598-020-68666-z DOI: https://doi.org/10.1038/s41598-020-68666-z
67. Salim, M.; Ramirez, G.; Clulow, A.J.; Hawley, A.; Boyd, B.J. Implications of the Digestion of Milk-Based Formulations for the Solubilization of Lopinavir/Ritonavir in a Combination Therapy. Mol. Pharmaceutics 2023, 20(4), 2256-2265. DOI: 10.1021/acs.molpharmaceut.3c00072 DOI: https://doi.org/10.1021/acs.molpharmaceut.3c00072
68. Tanaudommongkon, I.; Tanaudommongkon, A.; Dong, X. Development of in situ self-assembly nanoparticles to encapsulate lopinavir and ritonavir for long-acting subcutaneous injection. Pharmaceutics 2021, 13(6), Art. No: 904. DOI: 10.3390/pharmaceutics13060904 DOI: https://doi.org/10.3390/pharmaceutics13060904
69. Cattaneo, D.; Perno, C.F.; Rizzardini, G. A three-in-one, long-acting, nanosuspension reformulation of off-patent antiretrovirals for low-income and middle-income countries. AIDS 2018, 32(17), 2625-2627. DOI:10.1097/QAD.0000000000002011 DOI: https://doi.org/10.1097/QAD.0000000000001970
70. McConnachie, L.A.; Kinman, L.M.; Koehn, J.; Kraft, J.C.; Lane, S.; Lee, W.; Collier, A.C.; Ho, R.J. Long-acting profile of 4 drugs in 1 anti-HIV nanosuspension in nonhuman primates for 5 weeks after a single subcutaneous injection. J. Pharm. Sci. 2018, 107(7), 1787-1790. DOI: 10.1016/j.xphs.2018.03.005 DOI: https://doi.org/10.1016/j.xphs.2018.03.005
71. Koehn, J.; Iwamoto, J.F.; Kraft, J.C.; McConnachie, L.A.; Collier, A.C.; Ho, R.J. Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates. AIDS 2018, 32(17), 2463-2467. DOI: 10.1097/QAD.0000000000001969 DOI: https://doi.org/10.1097/QAD.0000000000001969
72. Perazzolo, S.; Shen, D.D.; Scott, A.M.; Ho, R.J. Physiologically based pharmacokinetic model validated to enable predictions of multiple drugs in a long-acting drug-combination nano-particles (DCNP): confirmation with 3 HIV drugs, lopinavir, ritonavir, and tenofovir in DCNP products. J. Pharm. Sci. 2024, 113(6), 1653-1663. DOI: 10.1016/j.xphs.2024.02.018 DOI: https://doi.org/10.1016/j.xphs.2024.02.018
73. Dominique, M.; Konstantin, H. (2016). Dosage form comprising lopinavir and ritonavir. U.S. Patent No. 9,370,578 B2. Washington, DC: U.S. Patent and Trademark Office.
74. Giardiello, M.N.; McDonald, T.O.; Owen, A.; Rannard, S.P. Compositions of lopinavir and ritonavir. International Publication number WO 2013/034927 A1.
75. Hampson, I.; Hampson, L. Lopinavir and ritonavir for the treatment of cervix disoprders. International Publication number WO 2019/224779 A1.
76. Pham, S.H; Choi, Y.; Choi, J. Stimuli-Responsive Nanomaterials for Application in Antitumor Therapy and Drug Delivery. Pharmaceutics 2020, 12(7), Art. No: 630. DOI: 10.3390/pharmaceutics12070630 DOI: https://doi.org/10.3390/pharmaceutics12070630
77. Koh, H.B.; Kim, H.J.; Kang, S.W.; Yoo, T.H. Exosome-Based Drug Delivery: Translation from Bench to Clinic. Pharmaceutics 2023, 15(8), Art. No: 2042. DOI: 10.3390/pharmaceutics15082042 DOI: https://doi.org/10.3390/pharmaceutics15082042
78. Asmamaw, M.; Zawdie, B. Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing. Biologics 2021, 15, 353-361. DOI: 10.2147/BTT.S326422 DOI: https://doi.org/10.2147/BTT.S326422
79. Kovarova, M.; Benhabbour, S.R.; Massud, I.; Spagnuolo, R.A.; Skinner, B.; Baker, C.E.; Sykes, C.; Mollan, K.R.; Kashuba, A. D. M.; García-Lerma, J. G.; Mumper, R. J.; Garcia, J. V. Ultra-long-acting removable drug delivery system for HIV treatment and prevention. Nat. Commun. 2018, 9(1), Art. No: 4156. DOI: 10.1038/s41467-018-06490-w DOI: https://doi.org/10.1038/s41467-018-06490-w
80. Khairkhah, N.; Namvar, A.; Bolhassani, A. Application of Cell Penetrating Peptides as a Promising Drug Carrier to Combat Viral Infections. Mol. Biotechnol. 2023, 65(9), 1387-1402. DOI: 10.1007/s12033-023-00679-1 DOI: https://doi.org/10.1007/s12033-023-00679-1
81. Kevadiya, B.D.; Ottemann, B.; Mukadam, I. Z.; Castellanos, L.; Sikora, K.; Hilaire, J. R.; Machhi, J.; Herskovitz, J.; Soni, D.; Hasan, M.; Zhang, W.; Anandakumar, S.; Garrison, J.; McMillan, J.; Edagwa, B.; Mosley, R. L.; Vachet, R. W.; Gendelman, H. E. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. Theranostics 2020, 10(2), 630-656. DOI: 10.7150/thno.39847 DOI: https://doi.org/10.7150/thno.39847
82. Jiang, J.; Ma, X.; Ouyang, D.; Williams, R. O. 3rd. Emerging Artificial Intelligence (AI) Technologies Used in the Development of Solid Dosage Forms. Pharmaceutics 2022, 14(11), Art. No: 2257. DOI: 10.3390/pharmaceutics14112257. DOI: https://doi.org/10.3390/pharmaceutics14112257
83. Hama, R.; Ulziibayar, A.; Reinhardt, J.W.; Watanabe, T.; Kelly. J.; Shinoka. T. Recent Developments in Biopolymer-Based Hydrogels for Tissue Engineering Applications. Biomolecules 2023, 13(2), Art. No: 280. DOI: 10.3390/biom13020280 DOI: https://doi.org/10.3390/biom13020280
84. Hu, M.; Ge, X.; Chen, X.; Mao, W.; Qian, X.; Yuan, W. E. Micro/Nanorobot: A Promising Targeted Drug Delivery System. Pharmaceutics. 2020, 12(7), Art. No: 665. DOI: 10.3390/pharmaceutics12070665 DOI: https://doi.org/10.3390/pharmaceutics12070665
85. Pan, X.; Veroniaina, H.; Su, N.; Sha, K.; Jiang, F.; Wu, Z.; Qi, X. Applications and developments of gene therapy drug delivery systems for genetic diseases. Asian J. Pharm Sci. 2021, 16(6), 687-703. DOI: 10.1016/j.ajps.2021.05.003 DOI: https://doi.org/10.1016/j.ajps.2021.05.003
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Dr Singireddy Anand Reddy, Dr Sobitha Rani
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
